Resmed Inc (RMD) Stock Price & Analysis
Resmed Inc (RMD) rose 1.97% to USD 196.94 as of June 9, 2026 at 22:34 UTC, according to Nexqual real-time market data.
RMD last closed at USD 193.14; the session ranged USD 193.75–197.34 on volume of 703,280 shares. Market capitalization is $28.57B, with a 52-week range of USD 180.27–293.81 (NYQ). Source: Nexqual, June 9, 2026 at 22:34 UTC.
Key Statistics (as of June 9, 2026 at 22:34 UTC)
| Price | USD 196.94 |
|---|---|
| Change | ▲ 1.97% (up) |
| Previous Close | USD 193.14 |
| Open | USD 194.44 |
| Day Range | USD 193.75 – 197.34 |
| 52-Week Range | USD 180.27 – 293.81 |
| Volume | 703,280 shares |
| Market Cap | $28.57B |
| Exchange | NYQ |
Technical Analysis (RMD)
Nexqual's technical model rates RMD "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 9, 2026 at 22:34 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 43.18 (neutral) |
| vs SMA50 | Below (USD 211.68) |
| MACD | -5.64 (negative) |
Analyst Ratings (RMD)
Wall Street analysts rate RMD "Buy" based on 15 analysts, with a mean price target of USD 270.6 (range USD 180–340), per Nexqual as of June 9, 2026 at 22:34 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 15 |
| Mean Target | USD 270.6 |
| High Target | USD 340 |
| Low Target | USD 180 |
| Buy / Hold / Sell | 11 / 7 / 1 |
Earnings (RMD)
| Next Earnings Date | 2026-04-30 |
|---|---|
| EPS Estimate | USD 2.9 |
| Revenue Estimate | $1.46B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 2.86 vs est 2.8 ▲ beat |
| 2025-12-31 | USD 2.81 vs est 2.72 ▲ beat |
| 2025-09-30 | USD 2.55 vs est 2.5 ▲ beat |
| 2025-06-30 | USD 2.55 vs est 2.48 ▲ beat |
Source: Nexqual, June 9, 2026 at 22:34 UTC.
Financials & Fundamentals (RMD)
| Total Revenue | $5.54B |
|---|---|
| Revenue Growth (YoY) | +10.80% |
| Gross Margin | +62.18% |
| Operating Margin | +35.33% |
| Profit Margin | +27.44% |
| ROE | +25.25% |
| Debt / Equity | 12.99 |
| Current Ratio | 3.01 |
| Total Cash | $1.66B |
| Total Debt | $843.17M |
| Free Cash Flow | $1.45B |
Source: Nexqual, June 9, 2026 at 22:34 UTC.
Financial Health Score (RMD)
Nexqual rates Resmed Inc's overall financial health "Strong" across five dimensions, as of June 9, 2026 at 22:34 UTC.
| Growth | Solid — Revenue +10% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 62%, operating 35% |
| Balance Sheet | Strong — $1.66B cash vs $843M debt, net cash position |
| Cash Flow | Strong — FCF $1.45B, 28% margin |
| Efficiency | Strong — ROE 25%, ROA 14.7% |
Ownership (RMD)
| Insider Ownership | +0.50% |
|---|---|
| Institutional Ownership | +69.99% |
| Shares Outstanding | 145.06M |
| Float | 144.16M |
| Short % of Float | +10.78% |
Source: Nexqual, June 9, 2026 at 22:34 UTC.
Leadership (RMD)
Resmed Inc is led by Michael J. Farrell BE, MBA, SM (age 53), CEO & Chairman, per Nexqual as of June 9, 2026 at 22:34 UTC.
| CEO & Chairman | Michael J. Farrell BE, MBA, SM (age 53) |
|---|---|
| Founder, Chair Emeritus & Non-Executive Director | Peter C. Farrell A.M., B.E., BE (Hons), Ph.D., ScD (age 83) |
| Chief Product Officer | Justin Leong (age 48) |
| Chief Financial Officer | Aaron Bloomer (age 39) |
| Chief Marketing Officer | Yvonne-Katrin Pucknat (age 49) |
Major Backers & Investors (RMD)
Notable institutional backers of Resmed Inc include Morgan Stanley, Invesco, Fidelity, according to Nexqual as of June 9, 2026 at 22:34 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Morgan Stanley | 1.85% |
| Invesco | 1.35% |
| Fidelity | 1.29% |
| First Trust Advisors LP | 1.06% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 22.4% |
| BlackRock | 9.64% |
| State Street | 5.78% |
| BNY Mellon | 3.4% |
| Geode Capital | 3% |
| Northern Trust | 1.19% |
Source: Nexqual, June 9, 2026 at 22:34 UTC.
From Resmed Inc's Latest SEC 10-K Filing (filed 2025-08-08)
Key Strengths & Strategy (as disclosed to the SEC)
- Another study published in Lancet Respiratory Medicine in 2019 estimated that mild to severe OSA impacts more than 936 million people worldwide, including 54 million Americans.
- Our leading Residential Care Software solutions are a key enabler of our Sleep and Breathing Health business, driving revenue synergies, contributing to demand generation and providing cohesion and interoperability for our AI-driven digital platform.
- Today, our Residential Care Software solutions support residential care providers serving more than 160 million individual patient accounts.
- Our quality management system is based upon the requirements of ISO 13485, Food and Drug Administration, or FDA, Quality System Regulation, or QSR, being replaced by the new FDA Quality Management System Regulation, or QMSR, effective February 2, 2026, European Medical Device Regulation, or MDR, the Medical Device Directive (93/42/EEC) and other applicable regulations for the markets in which we sell.
Partnerships
- In May 2025, we acquired VirtuOx, an IDTF, to expand our ability to partner with healthcare providers to help streamline the diagnostic process, while expanding collaboration with home medical equipment providers to efficiently support patients to start treatment. • Accelerate Market Growth through Awareness.
- If reciprocal tariffs go into widespread effect, they could have a material impact on our business and financial statements through interruption of supply chains, increases in our costs as our suppliers deal with an uncertain global trade environment or an increase or disruption of global shipping.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| COO | The Cooper Companies, Inc. | USD 68.62 | ▲ 1.9% |
| STE | STERIS plc (Ireland) | USD 212.88 | ▲ 0.25% |
| MTD | Mettler-Toledo International, I | USD 1,162.79 | ▲ 0.73% |
| IDXX | IDEXX Laboratories, Inc. | USD 578.89 | ▲ 2.98% |
| TFX | Teleflex Incorporated | USD 135.75 | ▲ 4.55% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 22:34 UTC. This page is informational and not investment advice.